| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Net loss | -14,964,875 | -14,433,881 | ||
| Unrealized loss from marketable securities | 0 | 0 | ||
| Comprehensive loss | -14,964,875 | -14,433,881 | ||
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.38 | -0.4 | ||
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.38 | -0.4 | ||
| Weighted-average common shares outstanding, basic (in shares) | 39,670,095 | 35,985,878 | ||
| Weighted-average common shares outstanding, diluted (in shares) | 39,670,095 | 35,985,878 | ||
Immuneering Corp (IMRX)
Immuneering Corp (IMRX)